MA56330B1 - Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone - Google Patents

Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone

Info

Publication number
MA56330B1
MA56330B1 MA56330A MA56330A MA56330B1 MA 56330 B1 MA56330 B1 MA 56330B1 MA 56330 A MA56330 A MA 56330A MA 56330 A MA56330 A MA 56330A MA 56330 B1 MA56330 B1 MA 56330B1
Authority
MA
Morocco
Prior art keywords
compound
self
compositions
tetrahydropyrazolopyrimidinone
pharmaceutical composition
Prior art date
Application number
MA56330A
Other languages
English (en)
Inventor
Francis Hubler
Dorte Renneberg
Simon Stamm
Raumer Markus Von
Mark Murphy
Michael Ambuehl
Elvire Fournier
Amandine Fraichard
Sylvie Froidevaux
Oliver Geiseler
Charlyse Herrmann
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA56330B1 publication Critical patent/MA56330B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques, qui sont auto-émulsifiantes, auto-microémulsifiantes ou auto-nanoémulsifiantes dans un milieu aqueux, comprenant le composé : 2-(2,2-difluoro-propyl)-5-[1-(2-fluoro-6-méthyl-phényl)-pipéridin-4-yl]-7-(2-trifluorométhylbenzyl)-2,4,5,7-tétrahydro-pyrazolo[3,4-d]pyrimidin-6-one et un mélange d'excipients comprenant un ou plusieurs excipient(s) lipophile(s) ; un ou plusieurs tensioactif(s) hydrophile(s) ; et éventuellement un ou plusieurs cosolvant(s) hydrophile(s). L'invention concerne en outre une forme cristalline dudit composé et son utilisation pour la préparation des présentes compositions. L'invention concerne en outre des utilisations pharmaceutiques des compositions pour la prévention/la prophylaxie ou le traitement de maladies et de troubles associés à des événements pathogènes associés à des niveaux élevés d'activation de c5a et/ou de c5ar.
MA56330A 2019-07-09 2020-07-08 Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone MA56330B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019068419 2019-07-09
PCT/EP2020/069230 WO2021005101A1 (fr) 2019-07-09 2020-07-08 Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone

Publications (1)

Publication Number Publication Date
MA56330B1 true MA56330B1 (fr) 2024-04-30

Family

ID=71409436

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56330A MA56330B1 (fr) 2019-07-09 2020-07-08 Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone

Country Status (23)

Country Link
US (1) US20220265658A1 (fr)
EP (1) EP3996682B1 (fr)
JP (1) JP2022540780A (fr)
KR (1) KR20220034821A (fr)
CN (1) CN114096252A (fr)
AU (1) AU2020312183A1 (fr)
BR (1) BR112021024038A2 (fr)
CA (1) CA3146386A1 (fr)
CL (1) CL2022000040A1 (fr)
ES (1) ES2974660T3 (fr)
HR (1) HRP20240381T1 (fr)
HU (1) HUE066112T2 (fr)
IL (1) IL289619A (fr)
MA (1) MA56330B1 (fr)
MX (1) MX2022000411A (fr)
MY (1) MY205685A (fr)
PH (1) PH12022550034A1 (fr)
PL (1) PL3996682T3 (fr)
RS (1) RS65511B1 (fr)
SG (1) SG11202113254PA (fr)
TW (1) TWI867008B (fr)
UA (1) UA128440C2 (fr)
WO (1) WO2021005101A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019137927A1 (fr) 2018-01-10 2019-07-18 Idorsia Pharmaceuticals Ltd Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires
WO2022259205A1 (fr) * 2021-06-11 2022-12-15 Universidade Da Beira Interior Composition auto-émulsifiante, ses procédés de production et ses utilisations
NL2028762B1 (en) * 2021-07-16 2023-01-23 Seranovo Holding B V Micelle-generating formulations for enhanced bioavailability
KR102810804B1 (ko) * 2023-01-20 2025-05-26 중앙대학교 산학협력단 소라페닙을 포함하는 자가나노유화 약물 전달 시스템 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104740A1 (en) * 2003-12-23 2007-05-10 Voorspoels Jody Firmin M Self-microemulsifying drug delivery systems of a hiv protease inhibitor
CN105705489B (zh) 2013-09-04 2019-04-26 百时美施贵宝公司 用作免疫调节剂的化合物
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
WO2015044900A1 (fr) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Composés immunomodulateurs thérapeutiques
WO2019137927A1 (fr) * 2018-01-10 2019-07-18 Idorsia Pharmaceuticals Ltd Dérivés de 2,4,6,7-tétrahydro-pyrazolo[4,3-d]pyrimidin-5-one et composés apparentés en tant que modulateurs du récepteur c5a pour le traitement de la vascularite et de maladies inflammatoires

Also Published As

Publication number Publication date
EP3996682A1 (fr) 2022-05-18
JP2022540780A (ja) 2022-09-20
RS65511B1 (sr) 2024-06-28
CL2022000040A1 (es) 2022-11-11
ES2974660T3 (es) 2024-07-01
TW202116323A (zh) 2021-05-01
MX2022000411A (es) 2022-02-10
PL3996682T3 (pl) 2024-06-03
TWI867008B (zh) 2024-12-21
UA128440C2 (uk) 2024-07-10
HUE066112T2 (hu) 2024-07-28
EP3996682C0 (fr) 2024-02-28
CN114096252A (zh) 2022-02-25
HRP20240381T1 (hr) 2024-06-07
MY205685A (en) 2024-11-06
WO2021005101A1 (fr) 2021-01-14
EP3996682B1 (fr) 2024-02-28
SG11202113254PA (en) 2021-12-30
US20220265658A1 (en) 2022-08-25
IL289619A (en) 2022-03-01
CA3146386A1 (fr) 2021-01-14
PH12022550034A1 (en) 2022-11-21
KR20220034821A (ko) 2022-03-18
BR112021024038A2 (pt) 2022-01-18
AU2020312183A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MA56330B1 (fr) Composition pharmaceutique comprenant un composé de tétrahydropyrazolopyrimidinone
Cassano et al. Tolerability issues during long-term treatment with antidepressants
Loo et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients
CA2353363A1 (fr) Granules a base d'amidon et de lactose
EP0559297B1 (fr) Utilisation des dérivés hétérocycliques pour la manufacture des médicaments
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
Dezzutti et al. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention: Dezzutti et al.
WO2018224736A3 (fr) Dérivés stéroïdiens thérapeutiquement actifs
Ekoka Mbassi Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults
FR3100128B1 (fr) Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
Ferrante et al. In vitro sensitivity of virulent Acanthamoeba culbertsoni to a variety of drugs and antibiotics
Jarwani Cardiovascular disease and antiretroviral therapy
JP2008540405A5 (fr)
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA45002B1 (fr) Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
John et al. A randomised, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data
MA58653B1 (fr) Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
ZA200507439B (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
Bhogal et al. Pharmacological treatment of social phobia
Orth-Gomer et al. Marital stress worsens prognosis in women with coronary heart disease. the Stockholm Female Coronary Risk Study
US20250025461A1 (en) Treatment of severe and uncomplicated malaria
Furgiuele et al. The effectiveness of 5-iodo-2-deoxyuridine in the treatment of herpes simplex keratitis
Siva et al. Antimicrobial drug ornidazole inhibits hamster sperm capacitation, in vitro
TH2101007827A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยสารประกอบเตตระไฮโดรไอโซควิโนลีน